other material
confidence high
sentiment neutral
materiality 0.70
Prime Medicine prices $150.9M public offering of common stock and pre-funded warrants
Prime Medicine, Inc.
- Offering of 19,200,001 shares at $6.25/share plus pre-funded warrants for 3,200,005 shares.
- Net proceeds estimated at approximately $150.9M after underwriting discounts and expenses.
- Proceeds to fund R&D, clinical development, and general corporate purposes.
- Closing expected on or about February 20, 2024, subject to customary conditions.
- Underwriters granted 30-day option to purchase up to an additional 3,360,000 shares.